Zhao Cong, Chen Jiaqi, Liu Hongji, Dai Yan
EyeSchool of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Department of Ophthalmology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.
Front Oncol. 2025 Aug 13;15:1619667. doi: 10.3389/fonc.2025.1619667. eCollection 2025.
Lung cancer is the second most common primary site for intraocular metastatic tumors, with the most frequent metastatic site being the choroid. However, cases of intraocular metastasis of lung cancer presenting as anterior uveitis or secondary glaucoma are rare and often misdiagnosed. Here, we report a case of a lung adenocarcinoma stage IV patient, who presented with anterior uveitis as the initial symptom without respiratory symptoms. After 28 months of follow-up, the patient received targeted treatment with Alectinib hydrochloride capsules and a series of timely ophthalmic surgeries. Following these treatments, the patient's intraocular and intracranial metastatic lesions disappeared, the primary pulmonary lesion significantly shrank, and the best corrected visual acuity (BCVA) improved from HM/30cm to 1.0. No significant toxic side effects were observed during the treatment, and the prognosis was favorable. The patient is currently living and working normally without complications. This case highlights the importance of considering metastatic tumors in patients with refractory anterior uveitis. Combined multimodal imaging and fluid biopsy can improve the early diagnosis rate of intraocular metastases. Targeted therapy based on genetic mutation detection, along with the appropriate timing for ophthalmic surgery, is crucial for improving patient prognosis.
肺癌是眼内转移性肿瘤的第二大常见原发部位,最常见的转移部位是脉络膜。然而,以眼前葡萄膜炎或继发性青光眼为表现的肺癌眼内转移病例罕见,且常被误诊。在此,我们报告一例IV期肺腺癌患者,该患者以眼前葡萄膜炎为首发症状,无呼吸道症状。经过28个月的随访,患者接受了盐酸阿来替尼胶囊靶向治疗及一系列及时的眼科手术。经过这些治疗,患者的眼内和颅内转移病灶消失,原发性肺部病灶显著缩小,最佳矫正视力(BCVA)从眼前手动/30cm提高到1.0。治疗期间未观察到明显的毒副作用,预后良好。患者目前正常生活和工作,无并发症。该病例凸显了在难治性眼前葡萄膜炎患者中考虑转移性肿瘤的重要性。联合多模态成像和液体活检可提高眼内转移的早期诊断率。基于基因突变检测的靶向治疗以及眼科手术的合适时机,对于改善患者预后至关重要。